| Literature DB >> 28536642 |
Yu Yang1, Junmeng Wei2, Xuekuan Huang1, Mingjun Wu3, Zhenbing Lv4, Pan Tong1, Rui Chang4.
Abstract
Background. Chronic renal failure (CRF) has become a global health problem and bears a huge economic burden. FuShengong Decoction (FSGD) as traditional Chinese medicine has multiple pharmacological effects. Objectives. To understand the underlying molecular mechanism and signaling pathway involved in the FSGD treatment of CRF and screen differentially expressed proteins in rats with CRF treated with FSGD. Methods. Thirty-three male Sprague-Dawley rats were randomly divided into control group, CRF group, and FSGD group. Differentially expressed proteins were screened by iTRAQ coupled with nanoLC-MS/MS, and these identified proteins were later analyzed by GO, KEGG, and STRING. Additionally, haptoglobin (HP) and alpha-1-antitrypsin (AAT) were finally verified by ELISA, Western blot, and real time PCR. Results. A total of 417 proteins were identified. Nineteen differentially expressed proteins were identified in the FSGD group compared with the model group, of which 3 proteins were upregulated and 16 proteins were downregulated. Cluster analysis indicated that inflammatory response was associated with these proteins and complement and coagulation cascade pathways were predominantly involved. The validation methods further confirmed that the levels of HP and AAT were significantly increased. Conclusions. HP and AAT may be the important biomarkers in the pathogenesis of CRF and FSGD therapy.Entities:
Year: 2017 PMID: 28536642 PMCID: PMC5425835 DOI: 10.1155/2017/1480514
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Differentially expressed proteins among control, model, and FSGD groups obtained by iTRAQ-nanoHPLC-MS/MS. 113: control; 114: model; 115: FSGD; —: ratio between 0.83 and 1.20.
| Protein ID | Protein name | 115:114 | 114:113 | 115:113 |
|---|---|---|---|---|
| sp∣P06866 | Haptoglobin | 0.10 | 12.62 | 1.74 |
| sp∣P04639 | Apolipoprotein A-I | 0.17 | 4.90 | — |
| sp∣Q6P734 | Plasma protease C1 inhibitor | 0.19 | 1.80 | 0.32 |
| sp∣P02651 | Apolipoprotein A-IV | 0.23 | 2.28 | 0.52 |
| sp∣P02764 | Alpha-1-acid glycoprotein | 0.25 | 1.87 | 0.45 |
| sp∣P09006 | Serine protease inhibitor A3N | 0.28 | 1.71 | 0.48 |
| tr∣D4A183 | Protein Vnn3 | 0.35 | — | 0.31 |
| sp∣Q03626 | Murinoglobulin-1 | 0.35 | — | 0.40 |
| sp∣Q63207 | Coagulation factor X | 0.36 | — | 0.37 |
| sp∣D3ZTE0 | Coagulation factor XII | 0.43 | 1.84 | 0.79 |
| tr∣Q68FY4 | Group specific component | 0.45 | 2.22 | — |
| sp∣P17475 | Alpha-1-antiproteinase | 0.46 | 2.74 | 1.25 |
| tr∣A9CME3 | Complement component 4 binding protein, alpha | 0.49 | 2.20 | — |
| sp∣P01015 | Angiotensinogen | 0.49 | 2.72 | 1.46 |
| tr∣G3V8B1 | Glycosylphosphatidylinositol specific phospholipase D1, isoform CRA_a | 0.58 | — | 0.67 |
| tr∣F1M6Z1 | Apolipoprotein B-100 | 0.73 | 4.60 | 3.30 |
| sp∣P02770 | Serum albumin | 1.28 | 0.79 | — |
| sp∣P31211 | Corticosteroid-binding globulin | 2.24 | 1.79 | 3.48 |
| sp∣Q01177 | Plasminogen | 2.90 | 0.35 | — |
Figure 1GO analysis of differentially expressed proteins.
Figure 2KEGG pathway mapping of differentially expressed proteins.
Figure 3The network of differentially expressed proteins obtained by STRING analysis.
Figure 4The expressions of HP and AAT among the control, model, and FSGD groups obtained by the ELISA, Western blot, and RT-qPCR methods. ((a) and (b)) The result of ELISA method. (c) The expression of each gene by RT-qPCR. (d) Western blot analysis for HP and AAT. (e) Densitometric analysis for HP and AAT. A P value less than 0.05 indicates statistical significance using the t-test. P < 0.001; P < 0.01. The bars represent the means ± standard deviations of ten rats.